Stratum Biosciences Raises $2M Seed to Scale AI-Driven Skin Biology Platform and Partnerships

New updates have been reported about Stratum Biosciences.

Stratum Biosciences has secured a $2 million seed round to accelerate development of its AI-driven skin biology discovery platform, with backing from Harvard Business School Alumni Angels of Greater New York and Skin Angels. Founded in 2024 by dermatologist and CEO Dr. Ross Lane Pearlman and dermatopathologist and President Dr. Buu Duong, the company is using the capital to scale its SkinSync™ platform, which mines more than 200,000 human skin samples to identify novel biomarkers and mechanisms for new dermatology and skincare solutions.

The company’s infrastructure expansion will be supported by its participation in NVIDIA’s Inception program, giving Stratum access to advanced computing resources to process its proprietary biopsy database at scale. According to Pearlman, the aim is to close long-standing knowledge gaps in skin biology, while Duong emphasizes that the platform is designed to move beyond observational research into decoding the “biological language” of skin, particularly in areas such as aging and longevity.

Stratum reports that SkinSync™ has already generated findings that challenge established assumptions about the skin barrier, which management believes can underpin new active ingredients and delivery systems. Chief Scientific Officer Dr. David Osborne, previously a co-founder of Arcutis, highlighted the pace of scientific progress on the platform and its potential to materially change dermatology R&D.

Commercial validation is already underway: over the past 12 months, Stratum has partnered with large global consumer packaged goods players and their subsidiaries to co-develop novel composition-of-matter actives and formulations with optimized bioavailability. These collaborations target high-value indications in skincare and dermatology, including hyperpigmentation and skin longevity, with an eventual pipeline that also spans eczema and broader skin health needs.

With fresh funding, Stratum plans to expand its portfolio of R&D and co-development partnerships focused on translating skin biology discoveries into proprietary ingredients and formulation technologies for both cosmetic and pharmaceutical applications. Operating from Johnson & Johnson’s JLABS incubator in New York, the company is positioning its IP-rich platform as a core enabler for global brands seeking differentiated, data-driven skin solutions and defensible innovation pipelines.